1. Scrip
  2. >>Business

Biocon Buoyant On ‘Unique Positioning’ Of Partnered COVID-19 Antibody

 
• By Anju Ghangurde

Biocon management signals the potential of its partnered entry with Serum Institute and Adagio Therapeutics into the communicable diseases segment. Continuing large supply opportunities for COVID-19 vaccines and prospects for boosters, alongside the promising profile of the neutralizing antibody being developed by its US-based partner, also bode well.

stop covid
Biocon's Partnered Foray Into Communicable Diseases Is Next Frontier • Source: Alamy

Biocon, Ltd.’s senior management has provided an upbeat outlook for the firm’s new business prong in the communicable diseases space, being driven via alliances with Serum Institute of India Pvt. Ltd. and US-based partner Adagio Therapeutics, Inc..

Biocon’s chairperson Kiran Mazumdar-Shaw said that the near-term focus of the "asset-light" Serum partnership will be on COVID-19 vaccines since a large part of the global population remains unvaccinated,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.